Saquinavir-13C6

Saquinavir-13C6 (Ro 31-8959-13C6) is 13C labeled Saquinavir (HY-17007) . Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells[1][2].

Product Specifications

Product Name Alternative

Ro 31-8959-13C6

UNSPSC

12352005

Target

Apoptosis; Calcium Channel; HIV; HIV Protease; Interleukin Related; Isotope-Labeled Compounds; JNK; NO Synthase; p38 MAPK; Reactive Oxygen Species (ROS) ; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; Others

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Cardiovascular Disease

Smiles

O=C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)[C@H](O)CN2[C@H](C(NC(C)(C)C)=O)C[C@@](CCCC3)([H])[C@@]3([H])C2)=O)C4=N[13C]5=[13C][13C]=[13C][13C]=[13C]5C=C4

Molecular Formula

C32 13C6H46N6O5

Molecular Weight

672.76

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Marco Donia, Danijela Maksimovic-Ivanic, Sanja Mijatovic, et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell cycle. 2011, 10 (3) : 492 - 499.|[3]Walmsley Sharon, Avihingsanon Anchalee, Slim Jihad et al. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009,50 (4) :367-374.|[4]Saquinavir|[5]Barillari Giovannia, Iovane Andréa, Bacigalupo Ilariaa, et al. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. AIDS. 2012, 26 (8) : 909-919.|[6]Martha Stefanidou, Carolina Herrera, Naomi Armanasco et al. Saquinavir Inhibits Early Events Associated with Establishment of HIV-1 Infection: Potential Role for Protease Inhibitors in Prevention. Antimicrob. Agents Chemother. 2012, 56 (8) : 4381-4390.|[7]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.